Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock Rated “Hold” by Sell-Side Brokerages

Posted by Brenda Bartman on Oct 6th, 2026

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) has received a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $14.00.

A number of brokerages have recently commented on TENX. Guggenheim lowered Tenax Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenax Therapeutics in a report on Thursday, September 10th. Evercore downgraded shares of Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Piper Sandler boosted their target price on shares of Tenax Therapeutics from $20.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, June 12th.

Read Our Latest Stock Report on TENX

Tenax Therapeutics Stock Performance

NASDAQ TENX opened at $1.96 on Tuesday. The firm’s fifty day moving average price is $4.09 and its two-hundred day moving average price is $10.26. The stock has a market cap of $73.34 million, a PE ratio of -1.32 and a beta of 0.92. Tenax Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $19.40.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. As a group, sell-side analysts predict that Tenax Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Tenax Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc purchased 900,000 shares of Tenax Therapeutics stock in a transaction on Thursday, September 3rd. The shares were purchased at an average price of $1.78 per share, for a total transaction of $1,602,000.00. Following the transaction, the insider owned 6,524,151 shares of the company’s stock, valued at approximately $11,612,988.78. This represents a 16.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Declan Doogan purchased 53,000 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was bought at an average cost of $1.92 per share, with a total value of $101,760.00. Following the purchase, the director owned 55,274 shares of the company’s stock, valued at approximately $106,126.08. This trade represents a 2,330.69% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 2,760,050 shares of company stock valued at $4,922,089. 10.81% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its holdings in Tenax Therapeutics by 989.3% during the 1st quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company’s stock worth $29,066,000 after purchasing an additional 1,648,808 shares during the last quarter. Perceptive Advisors LLC boosted its stake in shares of Tenax Therapeutics by 229.7% in the 1st quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company’s stock valued at $23,150,000 after purchasing an additional 1,008,640 shares during the last quarter. Braidwell LP bought a new stake in shares of Tenax Therapeutics in the 2nd quarter valued at $8,503,000. Bank of New York Mellon Corp acquired a new stake in shares of Tenax Therapeutics during the second quarter worth $4,733,000. Finally, Avidity Partners Management LP bought a new position in Tenax Therapeutics during the first quarter worth $3,453,000. 1.67% of the stock is owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases with significant unmet medical needs. The company’s research and development activities are centered on therapies intended to improve outcomes for patients with conditions affecting the heart and lungs.

Tenax’s primary product candidate is an oral formulation of levosimendan, a drug designed to enhance cardiac contractility and produce vasodilatory effects.